A Safety Study of ABI-007 for In-Stent Restenosis

NCT ID: NCT00093223

Last Updated: 2019-11-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 76 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-09-01
• Study Completion Date: 2007-12-01

Brief Summary

This trial will treat patients with a new chemotherapeutic medicine who have undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries. The purpose of the trial is to determine the appropriate dose of the new medicine for future trials and to evaluate the incidence of treatment-emergent adverse events and serious adverse events.

Detailed Description

See inclusion/exclusion criteria.

Conditions

Angina Pectoris; Coronary Artery Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

35mg/m\^2 infusion time is 3.5 minutes

Group Type: EXPERIMENTAL

Paclitaxel Nanoparticle Albumin Bound

Intervention Type: DRUG

Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).

Paclitaxel Nanoparticle Albumin Bound

Intervention Type: DRUG

2

2 doses of 35mg.m\^2 with the second dose given 2 months later

Group Type: EXPERIMENTAL

Paclitaxel Nanoparticle Albumin Bound

Intervention Type: DRUG

Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).

Paclitaxel Nanoparticle Albumin Bound

Intervention Type: DRUG

35mg/35 infusion time is 3.5 minutes

Interventions

Paclitaxel Nanoparticle Albumin Bound

Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).

Intervention Type: DRUG

Paclitaxel Nanoparticle Albumin Bound

Intervention Type: DRUG

Paclitaxel Nanoparticle Albumin Bound

35mg/35 infusion time is 3.5 minutes

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries
• Diagnosis of angina pectoris
• At least 18 yrs old
• If female, negative pregnancy test, non-lactating, and agree to utilize methods to prevent pregnancy
• No previous treatment for In-Stent Restenosis
• Patient agrees to comply with follow-up evaluation
• Informed Consent obtained
• Target vessel at least 3 mm diameter
• Total stent less than 25 mm
• Left ventricular ejection fraction at least 30%
• No more than a single stent will be used per lesion
• No more than one stented lesion per vessel with the exception that 2 lesions in a single vessel are allowable if covered by less than 25 mm of continuous stent
• By Intravascular Ultrasound (IVUS), stent is fully opposed and has a minimum diameter of 3 mm or an in-stent luminal area of at least 7 mm2
• TIMI 3 coronary flow post-stenting
• No angiographic evidence of thrombus post-stenting

Exclusion Criteria

• More than two lesions treated with Percutaneous Coronary Intervention (PCI) or it is anticipated that additional lesions will require treatment within two months
• Previous PCI within preceding three months
• Previous participation in another study within 30 days
• Life expectancy less than 12 months
• Factors making follow-up difficult
• Intended surgical intervention within 6 months of study participation
• Investigator decision that patient is unsuitable
• Recipient of heart transplant
• Q wave or non-Q wave Myocardial Infarction (MI) with documented total CK greater than 2X normal upper limits within the preceding 24 hrs and the CK and CK-MB enzymes remain above normal at the time of the procedure
• Cardiogenic shock
• May refuse blood transfusion
• Gastro-intestinal bleeding within past 3 months
• Platelet count less than 100,000 cells/mm3
• Impaired renal function
• Known allergies/hypersensitivity to aspirin, clopidogrel bisulfate, and/or stainless steel

• Intervention for another lesion occurred within 90 days or is planned for within 60 days after the index procedure
• Stent is located in a coronary bypass
• Unprotected left main disease with greater than 50% stenosis
• Lost a side branch greater than 2 mm during stenting procedure
• Angiographic evidence of thrombus post-stenting
• Prior stent within 5 mm of target lesion
• Left ventricular ejection fraction less than 30%
• Greater than 50% stenosis proximal or distal to target lesion
• Malposition, dissection, or unmasking of a significant narrowing in the inflow or outflow area of the implanted stent
• Patient has received a drug coated stent as part of this procedure

• Absolute neutrophil count is less than 1500 cells/mm3
• Platelet count is less than 100,000 cells/mm3
• Bilirubin greater than 1.5 mg/dl or SGOT and SGPT greater than 2.5X upper limit of normal or alkaline phosphatase greater than 2.5X upper limit of normal
• Creatinine greater than 2.5X upper limit normal
• Pre-existing peripheral neuropathy of NCI toxicity Criteria Scale of Grade greater than 1
• Immunosuppressed or has HIV or AIDS
• Hypersensitivity to Taxane

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celgene

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

José Iglesias, MD

Role: STUDY_DIRECTOR

Celgene Corporation

Locations

Abraxis BioScience, Inc.

Durham, North Carolina, United States

Countries

United States

Other Identifiers

CVR001

Identifier Type: -

Identifier Source: org_study_id